Advertisement As is the tradition here, towards the end of the year we take stock of what transpired in our respective industries and highlight important legal, regulatory, and business developments. For those of us who monitor the Food and Drug Administration (FDA or the Agency) and counsel FDA-regulated entities, it has certainly been a whirlwind … Continue reading FDA 2017 Year In Review: Therapeutic Products Energized by Cures Act, Bold Leadership